Cargando…
A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
BACKGROUND: Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175772/ https://www.ncbi.nlm.nih.gov/pubmed/35847693 http://dx.doi.org/10.1002/jha2.18 |
_version_ | 1784722521255313408 |
---|---|
author | Bryer, Emily J. Kallan, Michael J. Chiu, Ting‐Shan Scheuba, Katharina M. Henry, David H. |
author_facet | Bryer, Emily J. Kallan, Michael J. Chiu, Ting‐Shan Scheuba, Katharina M. Henry, David H. |
author_sort | Bryer, Emily J. |
collection | PubMed |
description | BACKGROUND: Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs. METHODS: A retrospective study analyzed 10,269 University of Pennsylvania Health System patients with malignancies of various type, stage, and histopathology who developed CIA between 2008 and 2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after adjusting for RBC and ESA intervention (all during the 90 days following CIA diagnosis). RESULTS: Among the 10,269 patients with CIA, 2,642 (25.7%) developed a VTE within the 90‐day period. VTE risk following RBC transfusion (HR = 1.37, 95% CI 1.24‐1.50, P < .001) was more than twice as common as VTE risk following ESA administration (HR = 0.53, 95% CI 0.40‐0.69, P < .001). CONCLUSION: While both RBC transfusion and ESA are independently associated with VTE, our data suggest a greater risk of VTE development with RBC transfusion as compared with ESA. |
format | Online Article Text |
id | pubmed-9175772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91757722022-07-14 A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration Bryer, Emily J. Kallan, Michael J. Chiu, Ting‐Shan Scheuba, Katharina M. Henry, David H. EJHaem Sickle Cell, Thrombosis, and Haematology BACKGROUND: Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs. METHODS: A retrospective study analyzed 10,269 University of Pennsylvania Health System patients with malignancies of various type, stage, and histopathology who developed CIA between 2008 and 2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after adjusting for RBC and ESA intervention (all during the 90 days following CIA diagnosis). RESULTS: Among the 10,269 patients with CIA, 2,642 (25.7%) developed a VTE within the 90‐day period. VTE risk following RBC transfusion (HR = 1.37, 95% CI 1.24‐1.50, P < .001) was more than twice as common as VTE risk following ESA administration (HR = 0.53, 95% CI 0.40‐0.69, P < .001). CONCLUSION: While both RBC transfusion and ESA are independently associated with VTE, our data suggest a greater risk of VTE development with RBC transfusion as compared with ESA. John Wiley and Sons Inc. 2020-05-26 /pmc/articles/PMC9175772/ /pubmed/35847693 http://dx.doi.org/10.1002/jha2.18 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Sickle Cell, Thrombosis, and Haematology Bryer, Emily J. Kallan, Michael J. Chiu, Ting‐Shan Scheuba, Katharina M. Henry, David H. A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration |
title | A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration |
title_full | A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration |
title_fullStr | A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration |
title_full_unstemmed | A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration |
title_short | A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration |
title_sort | retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: red blood cell transfusion versus erythrocyte stimulating agent administration |
topic | Sickle Cell, Thrombosis, and Haematology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175772/ https://www.ncbi.nlm.nih.gov/pubmed/35847693 http://dx.doi.org/10.1002/jha2.18 |
work_keys_str_mv | AT bryeremilyj aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT kallanmichaelj aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT chiutingshan aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT scheubakatharinam aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT henrydavidh aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT bryeremilyj retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT kallanmichaelj retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT chiutingshan retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT scheubakatharinam retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration AT henrydavidh retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration |